Trial reportBritish journal of cancer2026
Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial.
Trial report in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPre-clinical data demonstrated anti-tumour effect in Ewing sarcoma (ES) for zoledronic acid. This provided the rationale for the second randomisation (R2) in the EURO EWING 2012 (EE2012) trial, whether the addition of zoledronic acid to consolidation chemotherapy improved clinical outcomes.
methodsEE2012 was a European academic, open-label, randomised controlled phase III clinical trial. Patients with ES or Ewing-like sarcomas were included (R1). Patients meeting the R2 eligibility criteria (age 5-49 years) were randomised (1:1) to receive either nine cycles of zoledronic acid or no zoledronic acid with the R1 allocated consolidation chemotherapy. Primary and secondary outcome measures were event-free and overall survival, respectively.
findingsBetween 12-Aug-2014 and 20-Sep-2019, of the 640 R1 patients, 272 patients (136 in each group) were enrolled to R2. Median follow-up was 5.5 years. Three-year EFS was 59% in the zoledronic acid group and 57% in the no zoledronic acid group (adjusted hazard ratio = 0·92 (95% CI: 0·64, 1.31), p = 0.632). Three-year OS was 75% for both groups (adjusted hazard ratio = 0.84 (95% CI: 0.56, 1.25), p = 0.386).
conclusionAdding zoledronic acid did not improve clinical outcomes in ES.
trial registrationThe trial was prospectively registered with EudraCT 2012-002107-17 and ISRCTN 54540667.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.